VC-backed Aptinyx goes public
Aptinyx Inc, a biopharmaceutical company focused on developing treatments for neurologic disorders, has debuted its IPO after pricing its near 6.4 million shares at $16 per share. The stock began trading June 21, 2018 on the NASDAQ under the ticker symbol "APTX." J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets are the lead underwriters. Aptinyx's pre-IPO backers include Bain Capital Life Sciences, Adage Capital, Nan Fung Life Sciences, Rock Springs Capital, New Leaf Venture Partners, Frazier Healthcare Partners, Osage University Partners, Adams Street Partners and Beecken Petty O’Keefe & Company.
21 June 2018•3 mins read
